加密货币市场最近经历了显着的波动，特别是特朗普(CRYPTO:TRUMP)代币，其价值大幅下跌超过50%。 此次下跌正值梅拉尼娅·特朗普推出新的表情包币之际，这标志着一个值得注意的事件，因为这是首次有总统家族成员进入表情包币领域。 起初，唐纳德·特朗普的TRUMP ...

Hazer Group (ASX:HZR) has completed its commercial demonstration plant and reactor test program, marking a step in the company's technological advancements. The achievement is expected to ...

CardieX (ASX:CDX) has launched its CONNEQT Pulse and CONNEQT App in the United States. The Pulse, touted as the world’s most advanced personal arterial health monitor, has begun delivery to US ...

Recce Pharmaceuticals (ASX:RCE) has dosed all 30 patients in its Phase 2 clinical trial assessing the efficacy of RECCE 327 topical gel for the treatment of acute bacterial skin and skin structure ...

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company, has announced positive results from its ongoing Phase 1b clinical study evaluating the use of its INTASYL® siRNA gene ...

Neurizon Therapeutics (ASX:NUZ), a clinical-stage biotechnology company focused on neurodegenerative disease treatments, announced that the US Food and Drug Administration has placed a clinical hold ...

Japanese investment firm Metaplanet is aiming to expand its Bitcoin (CRYPTO:BTC) holdings to 10,000 BTC by the end of 2025, according to CEO Simon Gerovich. In a recent announcement, Gerovich detailed ...

Eliza Labs, the developer behind ai16z (CRYPTO:AI16Z), has released a white paper detailing its vision for Web3-native artificial intelligence agents. The document outlines the capabilities of Eliza, ...

Toronto-based Triple Flag Precious Metals Corp. (NYSE:TFPM) has reported record metal sales for the eighth consecutive year, according to its latest SEC filing. The company announced quarterly revenue ...

Government-owned electricity retailer Synergy has announced that CEO David Fyfe will leave the company in April. Deputy Chief Kurt Baker will step into the role on an interim basis while the utility's ...

Keros Therapeutics (NASDAQ: KROS) has voluntarily halted all dosing in its Phase 2 TROPOS trial due to safety concerns. The trial, which tested cibotercept (KER-012) for pulmonary arterial ...

The New South Wales Resources Regulator has announced its compliance priorities for January to June, outlining proactive programs and key focus areas aimed at enhancing safety and sustainability ...